SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol Myers Says KarXT Was Generally Well Tolerated in Both Studies

Bristol Myers said KarXT was generally well tolerated across both studies, with no new safety signals identified.

BMY

Related stories